DK91690A - Anvendelse af adamantan-derivater til fremstilling af terapeutiske praeparater til behandling af ischaemi - Google Patents

Anvendelse af adamantan-derivater til fremstilling af terapeutiske praeparater til behandling af ischaemi Download PDF

Info

Publication number
DK91690A
DK91690A DK091690A DK91690A DK91690A DK 91690 A DK91690 A DK 91690A DK 091690 A DK091690 A DK 091690A DK 91690 A DK91690 A DK 91690A DK 91690 A DK91690 A DK 91690A
Authority
DK
Denmark
Prior art keywords
treatment
ischaemi
preparation
atoms
hydrogen
Prior art date
Application number
DK091690A
Other languages
English (en)
Other versions
DK91690D0 (da
DK173356B1 (da
Inventor
Joachim Bormann
Markus R Gold
Wolfgang Schatton
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8201228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK91690(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of DK91690D0 publication Critical patent/DK91690D0/da
Publication of DK91690A publication Critical patent/DK91690A/da
Application granted granted Critical
Publication of DK173356B1 publication Critical patent/DK173356B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
DK199000916A 1989-04-14 1990-04-11 Anvendelse af adamantanderivater til fremstilling af terapeutiske præparater til behandling af cerebral iskæmi DK173356B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP89106657 1989-04-14
EP89106657A EP0392059B1 (de) 1989-04-14 1989-04-14 Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie

Publications (3)

Publication Number Publication Date
DK91690D0 DK91690D0 (da) 1990-04-11
DK91690A true DK91690A (da) 1990-10-15
DK173356B1 DK173356B1 (da) 2000-08-07

Family

ID=8201228

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199000916A DK173356B1 (da) 1989-04-14 1990-04-11 Anvendelse af adamantanderivater til fremstilling af terapeutiske præparater til behandling af cerebral iskæmi

Country Status (16)

Country Link
US (1) US5061703A (da)
EP (1) EP0392059B1 (da)
JP (1) JP2821233B2 (da)
AT (1) ATE94384T1 (da)
CA (1) CA2014453C (da)
CH (1) CH679208A5 (da)
DD (1) DD293493A5 (da)
DE (2) DE10299048I2 (da)
DK (1) DK173356B1 (da)
ES (1) ES2059602T3 (da)
HU (1) HU215592B (da)
IE (1) IE63467B1 (da)
LU (1) LU90988I2 (da)
NL (1) NL300107I2 (da)
PT (1) PT93763B (da)
SE (1) SE9001329L (da)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
DE19510189A1 (de) * 1995-03-21 1996-09-26 Hartmut Dr Goebel Verwendung von Amantadin
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
GB9802225D0 (en) 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
US20040248984A1 (en) * 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
PL373490A1 (en) 2001-08-29 2005-09-05 Eucro European Contract Research Gmbh & Co.Kg Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
GB0202161D0 (en) * 2002-01-30 2002-03-20 Vernalis Res Ltd Chemical compounds V
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
EP1556019A2 (en) 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RS20050851A (sr) * 2003-05-27 2008-04-04 Forest Laboratories Inc., Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja
CN100345819C (zh) * 2003-07-01 2007-10-31 北京德众万全药物技术开发有限公司 一种取代的金刚烷胺类化合物或其盐的制备方法
ITTO20030668A1 (it) 2003-09-02 2005-03-03 Rotta Res Lab S P A O Ra Rottapharm Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione.
CN1240668C (zh) * 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
AU2004316119B2 (en) * 2003-10-22 2008-04-24 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
US20050245617A1 (en) * 2004-01-29 2005-11-03 Meyerson Laurence R Methods and compositions for the treatment of CNS-related conditions
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
EA011290B1 (ru) 2004-06-17 2009-02-27 Мерц Фарма Гмбх Унд Ко. Кгаа Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
US8039009B2 (en) * 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
TW200621677A (en) * 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
WO2006034465A1 (en) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
CN100351225C (zh) * 2004-10-28 2007-11-28 中国医学科学院医药生物技术研究所 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用
BRPI0518483A2 (pt) 2004-11-23 2008-11-18 Neuromolecular Pharmaceuticals Inc composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US7462743B2 (en) * 2005-01-11 2008-12-09 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of memantine hydrochloride
KR101406456B1 (ko) 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
ITMI20050833A1 (it) * 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
WO2006122238A1 (en) * 2005-05-11 2006-11-16 Dr. Reddy's Laboratories Ltd. Process for preparing memantine
WO2006138227A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
BRPI0611966B1 (pt) * 2005-06-17 2022-05-03 Apogee Biotechnology Corporation Composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
PL1820792T3 (pl) 2006-02-21 2012-06-29 Hexal Ag Sposób otrzymywania adamantanoamin
DE102006009278B4 (de) * 2006-03-01 2010-06-02 Justus-Liebig-Universität Giessen Verfahren zur direkten Formamidierung oder Acetamidierung von Admantan und Admantanderivaten sowie deren Verwendung zur Herstellung von Aminoadmantanen
DE102006009279A1 (de) 2006-03-01 2007-09-06 Justus-Liebig-Universität Giessen Verfahren zur Herstellung von 1-Formamido-3,5-dimethyladamantan
ES2310504T1 (es) * 2006-03-27 2009-01-16 Teva Pharmaceutical Fine Chemicals S.R.L. Procedimiento para la preparacion de clorhidrato de memantina sustancialmente libre de impurezas.
WO2008002594A2 (en) * 2006-06-27 2008-01-03 Neuroprotection For Life Corp. Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US20080008743A1 (en) * 2006-07-06 2008-01-10 Forest Laboratories Holdings Limited Orally Dissolving Formulations of Memantine
PT2042480E (pt) * 2006-07-18 2013-06-24 Astellas Pharma Inc Derivado de aminoindano ou um seu sal
WO2008015271A1 (en) 2006-08-04 2008-02-07 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and the use as a medicine
WO2008062472A2 (en) * 2006-10-24 2008-05-29 Cadila Healthcare Limited Process for the preparation of memantine
US20100152108A1 (en) 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
US8648059B2 (en) * 2008-03-13 2014-02-11 The Regents Of The University Of California Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling
EP2103597A1 (en) 2008-03-20 2009-09-23 Merz Pharma GmbH & Co.KGaA Process for the manufacture of memantine and intermediate product
WO2009115334A2 (en) * 2008-03-20 2009-09-24 Merz Pharma Gmbh & Co. Kgaa Process for the manufacture of memantine and intermediate product
KR100998525B1 (ko) * 2008-03-28 2010-12-07 나노다이아몬드 주식회사 아밀로이드 올리고머 독성 억제제로서의 아다만탄 유도체
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
JP5778148B2 (ja) 2009-08-04 2015-09-16 メルク パテント ゲーエムベーハー 多環式炭水化物を含む電子デバイス
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
EP2578212B1 (en) 2010-05-24 2016-07-06 Farmalider, S.A. Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103282349A (zh) 2010-10-29 2013-09-04 德国麦氏大药厂 吲哚衍生物及其制备方法
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012085166A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012085167A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
US20140004189A1 (en) 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
WO2012152854A1 (en) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
EP2650284A1 (en) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
RU2014145682A (ru) 2012-04-14 2016-06-10 Интра-Селлулар Терапиз, Инк Органические соединения
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10329301B2 (en) 2013-12-20 2019-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6604957B2 (ja) 2014-02-04 2019-11-13 フォレスト・ラボラトリーズ・ホールディングス・リミテッド ドネペジル組成物及びアルツハイマー病を治療する方法
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev NMDA receptor antagonists for the treatment of Gaucher disease
MA42624A (fr) 2015-06-19 2021-04-28 Agenebio Inc Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
JP7251033B2 (ja) 2016-07-27 2023-04-04 コリウム， エルエルシー ドネペジル経皮送達システム
US10016372B2 (en) 2016-07-27 2018-07-10 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
WO2019246300A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2021014673A (es) 2019-05-31 2022-01-11 Tecnimede Soc Tecnico Medicinal Sa Combinacion de dosis fija de liberacion inmediata de memantina y donepezil.
EP4005565A1 (en) 2020-11-30 2022-06-01 Merz Pharmaceuticals GmbH Novel uses of adamantane derivatives
WO2023154014A1 (en) 2022-02-08 2023-08-17 Sahin Fikret Nmdar antagonists prevent ageing and aging-associated conditions and diseases through increasing 20s proteasome activity
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
US4748154A (en) * 1985-12-24 1988-05-31 Takeda Chemical Industries, Ltd. Peptide derivatives, their production and use
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer

Also Published As

Publication number Publication date
NL300107I1 (nl) 2003-02-03
HU215592B (hu) 1999-01-28
CA2014453C (en) 2000-03-28
EP0392059B1 (de) 1993-09-15
DD293493A5 (de) 1991-09-05
DK91690D0 (da) 1990-04-11
JPH02292214A (ja) 1990-12-03
CH679208A5 (da) 1992-01-15
DE58905637D1 (de) 1993-10-21
DE10299048I1 (de) 2003-03-27
LU90988I2 (fr) 2003-01-13
EP0392059A1 (de) 1990-10-17
CA2014453A1 (en) 1990-10-14
SE9001329L (sv) 1990-10-15
NL300107I2 (nl) 2003-02-03
US5061703A (en) 1991-10-29
HU902434D0 (en) 1990-08-28
PT93763A (pt) 1990-11-20
ES2059602T3 (es) 1994-11-16
DE10299048I2 (de) 2006-07-13
PT93763B (pt) 1996-04-30
ATE94384T1 (de) 1993-10-15
IE900996L (en) 1990-10-14
HUT58200A (en) 1992-02-28
DK173356B1 (da) 2000-08-07
SE9001329D0 (sv) 1990-04-11
JP2821233B2 (ja) 1998-11-05
IE63467B1 (en) 1995-04-19

Similar Documents

Publication Publication Date Title
DK91690A (da) Anvendelse af adamantan-derivater til fremstilling af terapeutiske praeparater til behandling af ischaemi
DK0585155T3 (da) Trifluormethylketon-peptidderivater med HLE-inhiberende aktivitet, deres fremstilling og farmaceutiske præparater
DK202882A (da) Fremgangsmaade til fremstilling af 1-alkyl-2-aminotetralinderivater
NO914960L (no) Medikamenter for canserterapi med antihistaminegenskaper
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE88468T1 (de) Arylalkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
DE69024778D1 (de) 2-Aminopyrimidin-4-carboxamid-Derivate, deren Herstellung und deren therapeutische Anwendung
AR005646A1 (es) Derivados de la quinolein-2-(1h)-ona, un procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos encalidad de medicamentos
TW249804B (da)
MY113062A (en) Amide derivatives and their therapeutic use
FR2617476B1 (fr) Nouveaux derives polycycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
ES2063157T3 (es) Nuevos derivados del indol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
SE9203824L (sv) Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ES2095714T3 (es) Nuevas amino-alquil-cromonas, sus procedimientos de preparacion y las composiciones farmaceuticas que las contienen.
DE68906827D1 (de) Phenothiazinderivate, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DE69704759D1 (de) Ellipticinederivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen
ES2169116T3 (es) Uso de los derivados de 2-amino purina en el tratamiento y profilaxis del virus 6 del herpes humano.
ES2068685T3 (es) Procedimiento de preparacion de nuevos derivados de 1,5-diin-cicloalquenos.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
CTFG Supplementary protection certificate (spc) issued

Free format text: PRODUCT NAME: MEMANTIN, HYDROCHLORID

Spc suppl protection certif: CA 2002 00028

Filing date: 20021031

PUP Patent expired
CTFL Supplementary protection certificate (spc) lapsed

Free format text: PRODUCT NAME: MEMANTIN, HYDROCHLORID; REG. NO/DATE: EU/1/02/219/001-006 20020515

Spc suppl protection certif: CR 2002 00028

Filing date: 20021031

Expiry date: 20100411